ReviewCurrent atherosclerosis reports2026
Targeting LDL Across the Whole Spectrum of Chronic Kidney Disease: From Pathophysiology to Novel Treatments.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe natural fate of chronic kidney disease (CKD) is the progression to dialysis; however, most patients face fatal and nonfatal cardiovascular events throughout their lifetime. We here address the role of low-density lipoprotein cholesterol (LDL-C) in the excess cardiovascular risk and the impact of traditional and innovative LDL-lowering therapies across the whole spectrum of CKD. RECENT
findingsCurrent guidelines on the prevention of atherosclerotic cardiovascular disease (ASCVD) from European and US cardiology societies recommend the assessment of total cardiovascular disease risk to modulate the intensity of preventive strategies in relation to the cardiovascular risk of patients: the higher the cardiovascular risk, the more intense should be the intervention. New drugs have demonstrated efficacy in achieving the lower LDL-C goals not attained by traditional therapy. The detection of vulnerable coronary plaque, rather than merely be the presence of luminal narrowing, provides an attractive imaging target to guide intensified preventive strategies in high-risk population including patients with CKD. In the context of CKD, the patient journey represents a dynamic, longitudinal care pathway in which cardiovascular risk progressively increases in parallel with declining renal function. Despite clear recommendations from nephrology and non-nephrology guidelines, treatment initiation, maintenance and intensification as well as LDL-C target are frequently overlooked in CKD population. Since novel LDL-lowering therapies provide additional therapeutic options for the patients with CKD, it is today mandatory to raise awareness on cardiovascular risk and to integrate lipid management into the broader, longitudinal care of patients with CKD across all stages of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.